RYAH Group Inc. (CSE: RYAH) Cannabis Clinical Trials Improve Due to Dose-Measuring Devices

June 25, 2021

June 25, 2021 13:55:05
  • Cannabis is a chemically variable plant making its clinical trials problematic, before the creation of dose-measuring devices
  • RYAH Smart inhalers being used in one of the largest clinical studies of its kind focused on chronic pain
  • Restrictive funding and legislative barriers regarding cannabis are rapidly dissipating
Regulating dose size in cannabis clinical trials has proven problematic from one test subject to another because cannabis is a chemically variable plant. RYAH Group (CSE: RYAH), a health care analytics and technology company, has created IoT dose-measuring devices backed by powerful data analytics, allowing for more control for variables within a clinical setting. In a recent article, RYAH outlined the history of cannabis clinical trials compared to how they are conducted in 2021. The full report can be found at… Read More>> NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW) 8033 Sunset Blvd Suite 1037-IW Los Angeles, CA 90046 310.299.1717 Office www.InvestorWire.com [email protected]

InvestorWire is part of the InvestorBrandNetwork.